The business story behind Wednesday’s FDA panel vote on GRAIL’s Galleri test is not really about GRAIL. It is about what happens to every other company racing to sell a multi-cancer blood test the moment a first approved product defines what “good enough” looks like.
The FDA’s Molecular and Clinical Genetics Devices Panel considered Galleri’s safety, effectiveness, and overall benefit-risk profile for screening adults aged 50 and older for multiple cancer types, voting 10-0 on safety, 7-2 with one abstention that benefits outweigh risks, and 6-4 on effectiveness. The split effectiveness vote is the number worth holding onto. Four of ten independent experts were not persuaded. The FDA is not bound by the committee’s recommendations, though it takes them into account when making final regulatory decisions. A formal FDA decision is still pending and the agency has not set a public decision date.
The advisory committee reviewed two major clinical studies conducted by GRAIL, including one involving more than 140,000 participants in England’s National Health Service and another of more than 35,000 North American participants, all over the age of 50. In those studies, adding Galleri to standard screening detected about four times as many cancers as standard screening alone in the UK study’s topline results, and GRAIL has also said that adding Galleri to recommended single-cancer screenings increased cancers detected by more than seven times versus recommended screening alone in a clinical study. That evidence base is the asset competitors must now reckon with.
The Category Trap
When a first mover wins regulatory approval in a nascent category, the approval becomes the floor, not the ceiling. Every subsequent applicant is measured against it. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law on February 3, 2026, establishes Medicare coverage for FDA-approved multi-cancer early detection screening tests beginning in 2028. That law rewards whoever the FDA approves, and it structurally disadvantages anything still operating as a laboratory-developed test when reimbursement kicks in.
Exact Sciences is already in the field. The company launched its Cancerguard multi-cancer early detection test as a laboratory-developed test in September 2025. But lab-developed status and PMA approval are different regulatory worlds. Cancerguard does not benefit from the 2028 Medicare coverage provision until it clears the same PMA process Galleri is going through, and it must do so against an evidence standard now anchored in two large studies totaling more than 175,000 participants.
Guardant Health’s situation is different but no simpler. The company has said it expects to expand into multi-cancer detection with its Shield platform, and the FDA has granted Breakthrough Device designation to its Shield multi-cancer detection test. Breakthrough designation speeds review but does not soften the clinical evidence bar. Phil Castle, director of the National Cancer Institute’s Division of Cancer Prevention, told the panel that tests like Galleri could do more harm by giving patients a false sense of security, particularly around claims of “early” detection. That skepticism shapes how the FDA will read any competitor’s data file too.
What Could Go Wrong for GRAIL
Even assuming FDA approval follows, the commercial picture carries real friction. The test is intended for people 50 and over, and GRAIL says it can detect signals shared by more than 50 types of cancer. That breadth is the clinical promise and the reimbursement challenge in the same sentence. Payers will want to see not just detection rates but evidence that earlier detection from Galleri translates into mortality reduction, data that a screening study of this scale takes years to generate. The FDA has highlighted the need to consider harm from false results and has discussed caveats in marketing, including warnings that a negative result does not rule out cancer and a positive result requires confirmatory diagnostic evaluation.
GRAIL is still unprofitable, and its valuation will move with expectations for how quickly FDA approval, Medicare reimbursement, and commercial scale arrive. If any of those slip, the stock can stop behaving like a category creator and start behaving like a company that has to wait.
The Verdict
For long-term capital allocators, the most durable insight from Wednesday is structural. GRAIL is not just filing for approval of a product. It is filing for the right to define what the multi-cancer detection category means, in regulatory language, for every company that follows. Exact Sciences and Guardant both have multi-cancer efforts, but neither has an FDA-approved multi-cancer screening PMA today. GRAIL’s president has said that approval will be a major trigger for evidence-based decisions with U.S. payers and could enable coverage decisions. If that logic holds, the companies still in lab-developed test status face a clock they did not set and cannot easily reset. The category is being written. The question investors should be asking is not whether they own GRAIL, but whether they understand who bears the cost of catching up.
